Bioindustry Park Announces the Sudden Death of Silvano Fumero

Bioindustry Park Canavese (Turin, Italy) announces with deepest
regret the sudden and untimely death of its President, Silvano Fumero,
who had also been its conceiver and founder in the early nineties.

After graduating from Turin University (Italy), Fumero (61 years
old) had a prestigious career in leading international health and
pharmaceutical companies and institutions. Its highlights are:

-- Antoine Marxer esearch Institute - RBM (Ivrea, Italy):

1972-1982, he covered various research posts becoming a Department
Head

1984-1987, in charge of Scientific Affairs

1987-1991, General Manager

-- EEC Brussels DG III (Chemical/pharmaceutical industry),
1982-1983

-- LCG Bioscience (London, England), 1991-1996, Vice President

-- Serono SA (Geneva, Switzerland), Executive Vice President,
Head of Research and Pharmaceutical Development, member of the
Executive Committee until 2002.

On returning to Italy, in 2003 he set up Creabilis Therapeutics
SpA, a biotech company situated in the Bioindustry Park working on the
discovery and development of novel therapeutic molecules for
inflammatory and dermatological illnesses with a high social impact.

In 2005 he created Eporgen Venture SpA, a new model for venture
capital to support the development of Italian businesses starting up
in the biotech sector.

Alongside his intense research activity, during which he published
many scientific papers, delivered speeches at important international
congresses, Silvano Fumero was a member of various associations in the
field and lectured on the Biotechnology Degree Course at Turin
University.

He had also a deep interest in culture, being a renowned author of
essays and novels, as well as an artist.

Bioindustry Park Canavese SpA is a science and technology park
located in the north of Italy near Turin. The Park promotes and
develops research in biotechnologies and life sciences, hosting
enterprises of the chemical, pharmaceutical, diagnostic,
bioengineering and iformation science fields. It offers research
facilities, scientific and support services, such as technology
transfer, patent support, tutorin/mentoring of start-ups and
spin-offs.

CREABILIS Therapeutics SpA is a drug discovery and development
biotech company that aims to discover, select, develop and bring to
commercial fruition novel and highly innovative therapeutic agents. A
considerable and diversified project/product portfolio has been
generated through an intense research activity. CREABILIS is strongly
committed to exploit the potential of its discovery assets and its
"know how" in the fields of inflammation / immunology, kinase
inhibition and cytokine networking, mainly in the area of "Skin
Pathologies".